Summary
This Form 8-K filing from Pfizer Inc. (PFE) on March 12, 2009, primarily concerns the financing arrangements for its previously announced Agreement and Plan of Merger with Wyeth, dated January 25, 2009. The report details the syndication of a $22.5 billion bridge term loan facility to an expanded group of twenty-nine lenders, in addition to the initial five lenders. This facility, administered by JPMorgan Chase, is intended to finance a portion of the consideration for the Wyeth acquisition. Investors should note that this filing signifies a key step in the financing of a major acquisition. The bridge loan agreement includes terms regarding interest rates, repayment, covenants, and events of default, which are standard for such large credit facilities. Pfizer and Wyeth are also preparing to file a Form S-4 Registration Statement which will include a proxy statement/prospectus for Wyeth stockholders, providing further details on the merger and urging investors to review these documents once available.
Key Highlights
- 1Pfizer Inc. has syndicated a $22.5 billion bridge term loan facility to finance a portion of the consideration for its merger with Wyeth.
- 2The syndication expanded the lender group to include twenty-nine additional lenders, alongside the initial five.
- 3JPMorgan Chase is acting as the administrative agent for the 364-day bridge loan credit agreement.
- 4The bridge facility is unsecured and provides flexible financing terms, including options for interest rate calculation and voluntary prepayments.
- 5The agreement includes standard covenants and events of default, with provisions for accelerated repayment and increased interest rates.
- 6Pfizer and Wyeth are in the process of filing a Form S-4 Registration Statement containing a proxy statement/prospectus for Wyeth stockholders regarding the merger.
- 7Investors are encouraged to read the upcoming proxy statement/prospectus for detailed information on the proposed merger.